Medications

Allergy to Plavix can be overcome: study

Allergies to Plavix, also know by its chemical name, Clopidogrel occur in about six percent of patients given the drug, vital for the prevention of life-threatening stent thrombosis after angioplasty and percutaneous coronary ...

Cardiology

Aspirin still first-line therapy for unstable angina/NSTEMI

(HealthDay) -- Aspirin is still the first line of therapy for patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI), and ticagrelor can be used in place of clopidogrel or prasugrel instead of aspirin ...

Cardiology

Omega-3 and blood-thinning drugs impact clotting process

Researchers in Poland have discovered that combining omega-3 fatty acids with two blood-thinning drugs, aspirin and clopidogrel, changed the process of blood clotting, potentially helping reduce the risk of heart attacks ...

Medications

Genetic test for Plavix use may be unneeded: study

A new study published Wednesday cast doubt on the usefulness of a genetic test for patients taking the anti-coagulant drug Plavix, calling into question last year's FDA warning about the blood thinner.

Genetics

World's first bedside genetic test proves effective

Tailored anti-platelet therapy, made possible through a novel point-of-care genetic test, optimizes treatment for patients who carry a common genetic variant, researchers at the University of Ottawa Heart Institute (UOHI) ...

Cardiology

Anti-clotting drugs yield similar results

The first trial to study patients with acute coronary syndrome who do not undergo coronary stenting or bypass surgery found no significant difference between two anti-clotting drugs – prasugrel and clopidogrel – in preventing ...

Cardiology

Results of the TRIGGER-PCI trial reported at TCT 2011

A clinical trial comparing prasugrel to clopidogrel for patients with high on-clopidogrel platelet reactivity (HCPR) following percutaneous coronary intervention (PCI) was ended early due to relatively few occurrences of ...

page 1 from 11

Clopidogrel

Clopidogrel is an oral, thienopyridine class antiplatelet agent used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It is marketed by Bristol-Myers Squibb and Sanofi-Aventis under the trade name Plavix. The drug works by irreversibly inhibiting a receptor called P2Y12, an adenosine diphosphate ADP chemoreceptor. Adverse effects include hemorrhage, severe neutropenia, and thrombotic thrombocytopenic purpura (TTP).

This text uses material from Wikipedia, licensed under CC BY-SA